Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
Condition: Non-Germline BRCA Mutated Ovarian Cancer Intervention: Drug: Olaparib Sponsors: AstraZeneca; Quintiles, Inc.; Myriad Genetics, Inc.; Covance; Theradex; Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Genetics | Ovarian Cancer | Ovaries | Research | Study